#
Atoltivimab, Maftivimab, and Odesivimab-ebgn
  • Professionals
  • AHFS Monographs

Atoltivimab, Maftivimab, and Odesivimab-ebgn

Class: Monoclonal Antibodies
Brands: Inmazeb

Medically reviewed by Drugs.com on Nov 9, 2020. Written by ASHP.

Introduction

Atoltivimab, maftivimab, and odesivimab-ebgn is a monoclonal antibody antiviral agent.

Uses for Atoltivimab, Maftivimab, and Odesivimab-ebgn

Atoltivimab, maftivimab, and odesivimab-ebgn has the following uses:

Atoltivimab, maftivimab, and odesivimab-ebgn is a combination of Zaire ebolavirus glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.

Atoltivimab, maftivimab, and odesivimab-ebgn has the following limitation(s) of use:

The efficacy of atoltivimab, maftivimab, and odesivimab-ebgn has not been established for other species of the Ebolavirus and Marburgvirus genera.

Zaire ebolavirus can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Zaire ebolavirus strains when deciding whether to use atoltivimab, maftivimab, and odesivimab-ebgn.

Atoltivimab, Maftivimab, and Odesivimab-ebgn Dosage and Administration

General

Atoltivimab, maftivimab, and odesivimab-ebgn is available in the following dosage form(s) and strength(s):

Injection: 241.7 mg of atoltivimab, 241.7 mg of maftivimab, and 241.7 mg of odesivimab per 14.5 mL (16.67 mg/16.67 mg/16.67 mg per mL) in a single-dose vial.

Dosage

It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Pediatric Patients

Dosage and Administration

The recommended dosage of atoltivimab, maftivimab, and odesivimab-ebgn is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion.

Atoltivimab, maftivimab, and odesivimab-ebgn must be diluted prior to administration.

Refer to the Full Prescribing Information for information on preparation and administration.

Adults

Dosage and Administration

The recommended dosage of atoltivimab, maftivimab, and odesivimab-ebgn is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion.

Atoltivimab, maftivimab, and odesivimab-ebgn must be diluted prior to administration.

Refer to the Full Prescribing Information for information on preparation and administration.

Cautions for Atoltivimab, Maftivimab, and Odesivimab-ebgn

Contraindications

None.

Warnings/Precautions

Hypersensitivity Reactions Including Infusion-associated Events

Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with a...